Drug intelligence / Profile preview

BP1.5375

Development stage: Discontinued
Lead developer: Bioprojet
Modality: Drug Delivery Systems
Administration: Oral

Overview

BP1.5375 is a drug developed by Bioprojet Pharma SARL. It was studied in a Phase 1 clinical trial (NCT01965301) that was terminated. The trial assessed the safety, tolerability, pharmacokinetics, and pharmacodynamics of single oral doses in healthy male subjects, and evaluated its effect on polysomnography compared to diphenhydramine and placebo. Based on its association with immethridine dihydrobromide, BP1.5375 is suggested to be a histamine H3 receptor agonist.

Other names: oxathridine derivative

Targets

HRH3 (Histamine Receptor H3)

Beyond the preview

Go deeper on BP1.5375.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BP1.5375.

Explore the full profile